EADV Presentation to Highlight New IL-13/IL-31 Bispecific Antibody

Data from a preclinical study of ZL-1503, an IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Netherlands, according to a release from Zai Lab Limited.

The results will address the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis, as well as other diseases involving the IL-13 and IL-31 pathways.

Medications that inhibit IL-4/IL-13 signaling have markedly improved the therapeutic landscape for AD. However, certain AD symptoms are mediated by IL-31, which is only partially attenuated by IL-4/IL-13 inhibition. As a result, many patients experience slow and modest clinical responses to currently available medications. Zai is evaluating the potential of ZL-1503 to inhibit both IL-13 and IL-31 signaling pathways.

“The potential to simultaneously target both inflammatory and pruritogenic pathways is important as it expands treatment options for individuals with atopic dermatitis and other related conditions,” said Rafael G. Amado, MD, President, Head of Global Research and Development, Zai Lab. “We look forward to sharing preliminary results from our preclinical study of ZL-1503 at EADV 2024.”